Andrei Shustov
Known title: Senior Vice President, MedicalCIK: 0001969686
Associated companies
Transaction History
| CLRB | ▲ Buy | Grant | 47,856 | $0 | 12/8/2023 | View on chart |
| CLRB | ▲ Buy | Grant | 47,856 | $0 | 12/8/2023 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Cellectar to Present Iopofosine Data at Waldenström Workshop
Cellectar Biosciences plans to share efficacy data from the Phase 2 CLOVER trial at an upcoming international workshop. The presentation will focus on patients with Waldenström Macroglobulinemia who did not respond to BTK inhibitor therapy. This data point is relevant for observers tracking the progress of the company's lead candidate, iopofosine I 131.
Cellectar to Present Iopofosine Data at Waldenström Workshop. Cellectar Biosciences plans to share efficacy data from the Phase 2 CLOVER trial at an upcoming international workshop. The presentation will focus on patients with Waldenström Macroglobulinemia who did not respond to BTK inhibitor therapy. This data point is relevant for observers tracking the progress of the company's lead candidate, iopofosine I 131.